EUCTR2018-001229-18-IT进行中（未招募）1 期
Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. - FIL_GAUDEALIS
FONDAZIONE ITALIANA LINFOMI ONLUS0 个研究点目标入组 43 人开始时间: 2021年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients diagnosed with grade 1, 2 or 3a positive CD20 FL confirmed histologically according to the WHO 2017 classification, relapsed or refractory;
- •Patients aged = 18 years;
- •Patients already treated for the FL with at least 2 previous lines of chemotherapy in combination with any anti-CD20 antibody;
- •Patients in need of treatment for the presence of at least one of the following criteria:
- •- bulky nodal or extra-nodal disease (with the exception of the spleen) defined as a mass with a diameter greater than 7 cm or involving at least 3 nodal or extra-nodal sites, each of them having a diameter greater than or equal to 3 cm ;
- •- at least one systemic symptom (fever> 38 ° C of uncertain etiology or nocturnal sweating or weight loss of more than 10% of body weight in the previous 6 months);
- •- symptomatic splenomegaly;
- •- organ compression syndrome (in particular, of the orbits, of the urethra, of the gastrointestinal tract, of the biliary tract);
- •- cytopenias related to lymphoma (hemoglobin <10 g / dL, and / or platelets <100,000 / mm3 and / or neutrophils <1,500 / mm3);
- •- serous effusion of the pleura or peritoneum;
- •- High LDH.
- •Eastern Cooperative Oncology Group (ECOG) performance status
- •Adequate haematological function (unless the anomaly is due to the underlying disease) independent of transfusions in the 28 days preceding the signing of the informed consent, defined as follows: neutrophils> 1,500 / mm3, platelets> 75,000 / mm3, hemoglobin> 8 , 0 g / dL;
- •Ability and willingness to adhere to the schedule of the study with regard to the planned visits and to everything else provided for by the protocol;
- •Ability to understand how much the study provides and voluntary signing of a written informed consent form;
- •Patients with the ability to swallow capsules and tablets;
- •Life expectancy = 2 months;
- •Female and male patients: readiness to follow a contraceptive plan, without interruption, from 28 days before the start of treatment (screening phase) up to 18 months after the end of treatment;
- •Male patients: refrain from giving the semen or sperm for the duration of the treatment and up to 18 months after the interruption of the same;
- •Female patients: regularly undergo pregnancy tests for the duration of the study.
- •Invia commenti
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 43
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 43
排除标准
- •Patients diagnosed with grade 3b FL or FL with evidence of transformation into high-grade non-Hodgkin's lymphoma;
- •Patients with involvement of the central or leptomeningeal nervous system by the lymphoma;
- •Major surgery within 28 days prior to signing informed consent;
- •Positive serology for HBV or evidence of active infection (HBsAg + or HBsAg patients with anti-HBs / anti-HBc positive antibodies and measurable viral DNA); if the viral DNA is negative or unmeasurable, the patient is eligible to study if HBsAg-;
- •Positive HVC viral RNA;
- •HIV seropositivity, regardless of viral load;
- •History of liver damage induced by pharmacological treatment, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic hepatopathy, non-alcoholic steatohepatitis, primary biliary cirrhosis, concomitant extrahepatic obstruction by cholelithiasis, liver cirrhosis or portal hypertension;
- •History of pneumonia induced by pharmacological treatment;
- •Concomitated inflammatory bowel pathology;
- •Concomitant addiction to drugs or alcohol;
- •Life expectancy <6 months;
- •Prevalent neoplasms other than FL in the last 10 years, except for localized carcinoma of non-melanomatous or squamous skin or in situ carcinoma of the uterine cervix;
- •Presence of any of the following alterations in laboratory values: liver enzymes (AST / SGOT and / or ALT / SGTP)> 2.5 times the upper limit of normal (except for changes due to the involvement of the liver by the lymphoma ); total bilirubin> 1.5 mg / dL (except for patients with Gilbert's syndrome or compression of the biliary tree by the neoplastic masses); creatinine clearance <30 mL / min;
- •Uncontrolled intercurrent diseases;
- •Known hypersensitivity or allergy to murine products or to any of the study drugs;
- •Pregnancy or breastfeeding, or reluctance to adopt adequate contraception;
- •Presence of any other serious medical condition, abnormal laboratory values ¿¿or psychiatric condition that would prevent the patient from giving informed consent by signing the consent form or that at the clinician's judgment would expose the patient to unacceptable risk if he participated in the study;
- •Any evidence of bacterial, viral or fungal infection in progress.
研究者
相似试验
进行中（未招募）
1 期
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT02537613Dana-Farber Cancer Institute54
已完成
2 期
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT02135133Dana-Farber Cancer Institute27
终止
1 期
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)CD20+ Follicular LymphomaNCT02391545SecuraBio55
已完成
2 期
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaNCT02736617OHSU Knight Cancer Institute10
撤回
1 期
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.Chronic Lymphocytic LeukemiaNCT02611908Michael Choi